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ABBREVIATIONS
GABAA Gamma-aminobutyric acid type
A
GABRB3 Gamma-aminobutyric acid type
A receptor b3 gene
The gamma-aminobutyric acid type A receptor b3 gene (GABRB3) encodes the b3-subunit of
the gamma-aminobutyric acid type A (GABAA) receptor, which mediates inhibitory signalling
within the central nervous system. Recently, GABRB3 mutations have been identified in a few
patients with infantile spasms and Lennox–Gastaut syndrome. We report the clinical and elec-
trographic features of a novel case of GABRB3-related early-onset epileptic encephalopathy.
Our patient presented with neonatal hypotonia and feeding difficulties, then developed phar-
macoresistant epileptic encephalopathy, characterized by multiple seizure types from 3
months of age. Electroencephalography demonstrated ictal generalized and interictal multifo-
cal epileptiform abnormalities. Using a SureSelectXT custom multiple gene panel covering 48
early infantile epileptic encephalopathy/developmental delay genes, a novel de novo GABRB3
heterozygous missense mutation, c.860C>T (p.Thr287Ile), was identified and confirmed on
Sanger sequencing. GABRB3 is an emerging cause of early-onset epilepsy. Novel genetic
technologies, such as whole-exome/genome sequencing and multiple gene panels, will
undoubtedly identify further cases, allowing more detailed electroclinical delineation of the
GABRB3-related genotypic and phenotypic spectra.
Gamma-aminobutyric acid type A (GABAA) receptors are
ligand-gated chloride channels that act as the primary
mediators of fast inhibitory synaptic transmission in the
central nervous system. They belong to the Cys-loop
superfamily, and are formed by pentameric assemblies of
different subunit subtypes: a1–a6, b1–b3, c1–c3, d, e, p, h,
and q1–q3.1 Most GABAA receptors contain two a-subu-
nits, two b-subunits, and another, most commonly a c-sub-
unit.2,3 These subunits have four transmembrane domains,
of which the second transmembrane domain forms a cen-
tral ion pore with the other four subunits4 (Fig. 1a). When
GABA, the physiological ligand of GABAA receptors binds
to the receptor, the ion pore opens, facilitating chloride
influx or efflux. The direction of chloride flux depends on
intracellular chloride concentration, regulated by the potas-
sium-chloride KCC2 and sodium–potassium–chloride
NKCC1 co-transporters. In developing brains, the pre-
dominance of NKCC1 leads to increased intracellular
chloride, resulting in GABA-mediated chloride efflux
which depolarizes the cell membrane, thus leading to neu-
ronal excitation.5 Mature neuronal cell bodies have low
intracellular concentrations of chloride due to high levels
of KCC2 expression, leading to GABA-mediated chloride
influx that hyperpolarizes the cell membrane leading to
neuronal inhibition.6
Given the central inhibitory role of GABAA receptors, it
is not surprising that, to date, several genetic epilepsy syn-
dromes have been associated with variants in GABAA
receptor subunit genes including GABRA1, GABRB3,
GABRD, and GABRG2.7 GABRB3, located on chromosome
15q11.2-q12, encodes the b3-subunit of the GABAA recep-
tor. Reduced GABRB3 expression has been postulated in
the pathogenesis of absence seizures, abnormal sensory
processing, and other neurodevelopmental disorder pheno-
types such as Angelman syndrome, autism spectrum disor-
ders, and intellectual disability.8–10 Furthermore, single
nucleotide polymorphisms and missense mutations in
GABRB3 have previously been implicated in childhood
absence epilepsy.11,12
In 2013, GABRB3 mutations were identified in patients
with infantile spasms and Lennox–Gastaut syndrome.13 To
date, few cases of GABRB3 epileptic encephalopathy have
been described in the literature. We report a case of early-
onset epilepsy with a de novo GABRB3 mutation identified
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on a diagnostic multiple gene panel, and delineate the elec-
troclinical phenotype in our patient.
CASE REPORT
A male, first-born to unrelated white parents, was deliv-
ered after induction of labour, by forceps delivery at 42
weeks’ gestation. The antenatal period was unremarkable
and he was born in good condition. His maternal grand-
father reported having seizures in childhood provoked by
startling, but these resolved spontaneously and there were
no further neurodevelopmental concerns. Family history
was otherwise non-contributory. The patient presented
with neonatal hypotonia, feeding difficulties, and failure
to thrive in early infancy. At 3 months of age, he devel-
oped clusters of short seizures characterized by eye devia-
tion, eyelid flickering, tonic arm extension, and back
arching. Ictal electroencephalography (EEG) revealed gen-
eralized fast activity, more prominent over the frontal
regions, and interictal recordings showed high-amplitude
delta/theta multifocal (but predominantly right anterior)
discharges (Fig. 1b). Initially, complete cessation of sei-
zures was achieved in response to therapeutic doses of
the GABA transaminase inhibitor vigabatrin. However,
severe hypotonia, sedation, and respiratory difficulties
ensued, hence the patient was weaned off vigabatrin and
it was discontinued. Seizures recurred at 5months of age,
and, despite multiple antiepileptic therapies (initially car-
bamazepine 14 mg/kg/day; then levetiracetam 40 mg/kg/
day, topiramate 4 mg/kg/day, and sodium valproate
25 mg/kg/day in combination; and finally ketogenic diet
with levetiracetam up to 50 mg/kg/day), he continued to
have ongoing intractable epilepsy. At the time of last
review, age 3 years 2 months, he had 10 to 20 epileptic
seizures per day. Seizure semiology was varied, with epi-
sodic behavioural arrest, focal motor events, myoclonic
jerks, and brief tonic seizures with lower-limb extension.
Parents also reported frequent paroxysms of laughter of
undetermined origin, but these episodes have not been
captured on EEG.
Over time, he developed severe global developmental
delay with signs of slow progress but no obvious evidence
of regression. At 3 years 2 months, head circumference
plotted on the 0.4th centile. A few subtle dysmorphic fea-
tures were evident, including mild prominence of his fore-
head with long eyelashes, tented mouth appearance, high-
arched palate, and bilateral undescended testes. There was
also marked axial hypotonia and severe head lag. An overall
paucity of limb movements was observed, although some
antigravity movements were evident. Peripheral tone was
low/normal, deep tendon reflexes were brisk throughout,
and plantar responses up-going bilaterally. There was no
evidence of ankle clonus. He could make some vocaliza-
tions and was feeding orally with only occasional drooling,
and no episodes of choking or swallowing difficulties.
Extensive neurometabolic investigations were essentially
unremarkable (Table SI, online supporting information),
including a normal MRI brain (age 14 mo) and compara-
tive genomic hybridization microarray analysis for genomic
copy number variants.
MOLECULAR GENETIC INVESTIGATION
Further diagnostic testing was undertaken using a multiple
gene panel covering 48 genes (Table SII, online supporting
information) causing early infantile epileptic encephalopa-
thy. A custom SureSelect library was created (Agilent’s
SureDesign tool, https://earray.chem.agilent.com/sure-
design/). Libraries were made following the SureSelectXT
Custom Capture protocol (Agilent Technologies, Santa
Clara, CA, USA) and sequenced in-house on an Illumina
MiSeq. Of targeted regions (target genes and their intron–
exon boundaries), 99.7% were covered at ≥309. A single
heterozygous missense mutation of GABRB3 (c.860C>T,
p.Thr287Ile) was identified (Fig. 1a). Subsequent Sanger
sequencing of both proband and parents confirmed these
findings, establishing that the mutation was absent in the
parents and likely to have occurred de novo (Fig. S1,
online supporting information). The variant identified is
classified as ‘likely pathogenic’ according to the American
College of Medical Genetics/Genomics Standards and
Guidelines,14 which infers greater than 90% certainty of
being disease-causing. This variant occurred de novo, pro-
viding strong evidence of pathogenicity. It was absent in
control population databases including ExAC (http://
exac.broadinstitute.org/), 1000 Genomes (http://brow-
ser.1000genomes.org/index.html), and Exome Variant Server
(http://evs.gs.washington.edu/EVS/) (moderate evidence).
Furthermore, the amino acid change occurs in a transmem-
brane domain lining the ion channel pore4 (moderate evi-
dence). In silico analysis provided further evidence of
pathogenicity, with Polyphen2 (score 1.000, sensitivity 0.00,
specificity 1.00), SIFT (score 0.000), and PROVEAN (score
5.65) predicting the variant to be probably damaging,
damaging, and deleterious, respectively.
DISCUSSION
We report a novel mutation in GABRB3 in a patient with
severe intractable early infantile epileptic encephalopathy.
Our report highlights the recent finding that mutations in
GABRB3 are an emerging cause of early-onset epilepsy
syndromes.
To date, five other cases of GABRB3 early infantile
epileptic encephalopathy have been reported,10,13 to our
knowledge (Table I). We postulate that there are several
What this paper adds
• A report of a novel GABRB3 mutation associated with early infantile epilep-
tic encephalopathy.
• A detailed description of the clinical and electrographic features of the
case.
• A review of the few other reported cases of GABRB3-related epileptic
encephalopathy.
• A discussion of this gene’s association with other neurodevelopmental disor-
der phenotypes.
• Increased clinical awareness of the role of multiple gene panels in the diag-
nosis of early infantile epilepsy.
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features common in all these cases, including: (1) seizure
onset in infancy, <10months of age, (2) multiple seizure
types including infantile spasms, (3) variable EEG abnor-
malities, and (4) associated comorbidities such as neurode-
velopmental delay, attention-deficit–hyperactivity disorder,
autistic features, and intellectual disability. Similar to pre-
vious reported cases, our patient manifested features of a
non-specific early infantile epileptic encephalopathy disor-
der, with multiple seizure types and significant delay in
development.
Our patient harboured a mutation affecting a highly
conserved protein domain located in the second transmem-
brane loop lining the ion channel (Fig. 1a). It is difficult to
postulate what the exact pathogenic mechanism of this
variant is without any in vitro or in vivo functional work;
however, it is probably due to loss of function and haploin-
sufficiency. It is possible that the position of the amino
acid change within the receptor pore could negatively
impact on receptor function, for example by inhibiting the
pore’s opening and subsequent chloride flux. Other mecha-
nisms including reduced GABRB3 protein expression and
incorrect cellular trafficking of GABRB3 could also play a
role. This is the first reported mutation affecting this
region and, to date, most other reported GABRB3 muta-
tions causing epileptic encephalopathies target the extracel-
lular protein domains, near the amino (N)0 terminus13
(Fig. 1a).
GABRB3 has also been implicated in other neurodevel-
opmental disorders such as autism, childhood absence epi-
lepsy, and Angelman syndrome. A single nucleotide
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Figure 1: (a) Top: Schematic diagram of the gamma-aminobutyric acid type A (GABAA) receptor and the gamma-aminobutyric acid type A receptor b3
(GABRB3) subunit (depicted on the left). Most physiological heteromeric GABAA receptors are thought to include two a-, two b-, and one other (most
frequently a c-) subunits. Bottom: Each b3-subunit consists of an extracellular domain, an a-helical M1–M4 transmembrane bundle, and an M3–M4
intracellular loop. The M2 segments line the ion channel pore that tapers as it traverses towards the intracellular side of the membrane. The de novo
heterozygous mutation in GABRB3 in our proband is located in amino acid position 287. Thr287 is located in the M2 segment. Previously reported muta-
tions in patients with epileptic encephalopathies are located in amino acid positions 110, 120, 138, 180, and 302. Polymorphisms and mutations impli-
cated in childhood absence epilepsy are in positions 11, 15, and 32, clustered closer to the N terminus. All above mutations and variants are depicted
as circles with corresponding numbers. (b) Interictal electroencephalogram (EEG) recording is seen above, showing high-amplitude multifocal dis-
charges, particularly in the right anterior region (circle). Ictal EEG is depicted below, demonstrating generalized fast activity, more prominent over the
frontal regions.
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polymorphism at the promoter region of GABRB3 (T>C
substitution in position 897, numbering with respect to
the initiator methionine of exon 1a), which leads to reduc-
tion of the promoter’s transcriptional ability, has been
associated with childhood absence epilepsy in previous
studies.12 Other researchers have reported that a rare
GABRB3 single nucleotide polymorphism (c.31C>T;
p.Pro11Ser)15 and other variants (c.44C>T; p.Ser15Phe,
and c.94G>A; p.Gly32Arg) (NM_021912.4) are linked with
childhood absence epilepsy phenotypes associated with
eyelid myoclonus and generalized tonic–clonic seizures.6,11
Probands had typical generalized 3Hz spike and wave dis-
charges during childhood, with clinical symptoms later
remitting, without neurological sequelae. The identified
mutations were also present in other family members who
never had epileptic seizures, suggesting variable pene-
trance. The same mutations were not found in 630 healthy
ethnically and sex-matched comparison individuals in one
study. However, p.Pro11Ser was later described in an
asymptomatic individual, suggesting it may be a rare single
nucleotide polymorphism.6,15 Interestingly, genetic variants
implicated in childhood absence epilepsy are clustered
much closer to the N-terminal domain of the protein than
those identified in GABRB3 early infantile epileptic
encephalopathy (Fig. 1a).
In Angelman syndrome, deletions encompassing
GABRB3 have been reported.16 Mice with Gabrb3 knock-
out have epilepsy and other abnormalities that show some
similarities to patients with Angelman syndrome.17 The
extent to which GABRB3 accounts for the clinical pheno-
type of Angelman syndrome is currently unclear. Other
genes including GABRG3 and GABRA5 are also often con-
tained within deletions causing Angelman syndrome.16 The
more severe phenotype associated with such deletions
might indicate an additive role for these genes in disease
pathogenesis. EEG recordings in Angelman syndrome
often demonstrate specific rhythmic patterns that are less
prominent in patients with deletions encompassing
GABRB3. Indeed, no such rhythmicity was evident in our
participant.
At present, there are too few reported cases of GABRB3-
related epilepsy for clear phenotype–genotype correlations
or comparisons with Angelman syndrome due to chromo-
some deletions with GABRB3 haploinsufficiency. It is cur-
rently unknown whether mutation type and location affect
clinical disease presentation, or whether other environmen-
tal or epigenetic factors may play a role. Increasing avail-
ability of novel genetic technologies, such as multiple gene
panels and whole-exome sequencing will undoubtedly
accelerate the identification of further cases, allowing more
detailed delineation of the spectrum of GABRB3-related
disorders.
Recent studies suggest that GABRB3 mutations cause
attenuated chloride currents and channel activity impair-
ment through subunit hyperglycosylation.11 The mecha-
nisms through which GABRR3 mutations affect neuronal
Table I: Reported patients with early-onset epileptic encephalopathy due to GABRB3 mutations
Mutation
De
novo/
inherited
Age
at
onset
(mo)
Seizure
semiology EEG
Seizure
evolution and
treatment response
if reported
Other
features
Intellectual
disability References
c.328A>G;
p.Asn110Asp
De novo 5 Infantile
spasms
Myoclonic
seizures
Hypsarrhythmia No follow-up data None
reported
None at
presentation;
no follow-up
data
Allen
et al.13
c.358G>A;
p.Asn120Asp
De novo 10 Infantile
spasms
Generalized
2Hz bursts
Lennox–Gastaut
syndrome
ADHD
Impulsivity
Severe Allen
et al.13
c.413_415dupACC;
p.Asn138_
Arg139insHis
De novo 2 Myoclonic
Focal seizures
Atonic head
nods
Multifocal/
modified burst
suppression
Responsive to
levetiracetam and
topiramate
‘Mild’
autistic
features
Severe Hamdan
et al.10
c.539A>G;
p.Glu180Gly
De novo 10 Infantile
spasms
Generalized
2Hz bursts
Lennox–Gastaut
syndrome
ADHD
Impulsivity
Sleeping
difficulties
Severe Allen
et al.13
c.905A>G;
p.Tyr302Cys
De novo 10 Focal
dyscognitive
seizures
Behavioural
arrests
Slow, some left
temporal
features
Lennox–Gastaut
syndrome
None
reported
Severe: 20
words at 4y
Allen
et al.13
c.860C>T;
p.Thr287Ile
De novo 3 Focal motor
seizures
Tonic seizures
Generalized
fast activity.
Interictal delta/
theta
multifocal
discharges
Ongoing seizures
with behavioural
arrests, focal
motor, myoclonic,
tonic seizures
None
currently
Severe This paper
ADHD, attention-deficit–hyperactivity disorder; EEG, electroencephalography.
4 Developmental Medicine & Child Neurology 2015
networks giving rise to epilepsy and neurodevelopmental
delay are yet to be fully elucidated. Further research is
needed, not only to understand the underlying disease
pathogenesis but also to identify novel therapies, which
may also have wider implications for GABAA modulation
in other neurological disorders.
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SUPPORTING INFORMATION
The following additional material may be found online:
Figure S1: Top panel: De novo heterozygous mutation in
GABRB3, c.860C>T (p.Thr287Ile) detected by panel and con-
firmed by Sanger sequencing (red rectangle).
Table SI: Neurometabolic investigations undertaken in patient.
Table SII: Epilepsy and severe delay gene panel result.
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